Finanzierte Projekte





2023Unstructured proteins as therapeutic targets for neuromuscular diseases2Dr. Leonidas Emmanouilidis, ETH Zürich
2023Open and reproducible pipeline for the acquisition and analysis of muscle MRI data in Facioscapulohumeral Muscular Dystrophy1Dr. Claudia Weidensteiner, University Hospital Basel
2023Dissecting lysosomal signals to fight Pompe disease1Dr. Andrea Armani, University of Zürich
2023Functional properties and epigenetic signature of quiescent and early activated human muscle reserve cells3Dr. Thomas Laumonier, University of Geneva
2022Activation of human skeletal muscle stem cells:role of Orai3 and its partner AHNAK2 in physiological condition and in Duchenne muscular dystrophy3Prof. Maud Frieden, University of Geneva
2022Understanding the clinical spectrum associated with VMA21 deficiency3Prof. Perrine Castets, University of Geneva
2022ANTXR2 as a key player in Collagen VI signaling in muscle stem cells: New therapeutic perspectives for COL6-related myopathies2Prof. Gisou van der Goot, EPFL Lausanne
2022Molecular mechanisms of complement activation and neuromuscular disruption by combinations of autoantibodies from patients with Myasthenia Gravis3Dr. Nicholas Sanderson, University Hospital Basel
2021From the investigation of the role of SRSF1 in ALS/FTD to its targeting as a therapeutic strategy3Prof. Frédéric Allain, ETH Zürich
2021Molecular crosstalk between muscles and motor neurons and its role in neuromuscular circuit formation2Prof. Patrick Tschopp, University of Basel
2021Molecular Diagnosis and Coping Mechanisms in Mitochondrial Myopathies3Prof. Alexis Jourdain, University of Lausanne
2021IPRIMYO: Immune-privileged, immortal, myogenic stem cells for gene therapy of Muscular Dystrophy
(Paul Pettavino Fellowship)
2Dr. Marisa Jaconi, University of Geneva
2021Effect of RYR1 mutations on muscle spindle function and their impact on the musculoskeletal system2Profs. Susan Treves and Francesco Zorzato, University Hospital Basel
2021Therapeutic potential of human myogenic reserve cells in Duchenne Muscular Dystrophy1Dr. Thomas Laumonier, University of Geneva
2021Glutamine metabolism as a potential target for Duchenne Muscular Dystrophy1Dr. Inés Soro-Arnàiz, ETH Zürich
2021Targeting protein s-acylation during Tubular Aggregate Myopathy2Dr. Amado Carreras, University of Geneva
2021Aggravating the phenotype of dystrophic mice for improving preclinical research and clinical translation for Duchenne muscular dystrophy1Dr. Olivier Dorchies, University of Geneva

Characterization of autoreactive T cells in Guillain-Barré syndrome
(Paul Pettavino Fellowship)

3Dr. Daniela Latorre, ETHZ, Zürich
2020A vascularized human muscle-on-a-chip to elucidate the contribution of endothelial-mesenchymal transition on the progression of muscular dystrophies3Dr. Simone Bersini, Ente Ospedaliero Cantonale, Lugano
2020Characterization of a novel form of ALS associated with changes in the sphingolipid metabolism3

Dr. Museer Lone,
University of Zürich

2020Pre-clinical treatment of mouse models carrying recessive Ryr1 mutations with HDAC/DNA methyltransferase inhibitors.1Profs. Susan Treves and Francesco Zorzato, Basel University Hospital
2020New aspects of TGFβ signaling in muscle homeostasis and regeneration3

Dr. Michael Bachmann
University of Geneva

2020Inhibition of sphingolipid synthesis as a treatment strategy for Duchenne muscular dystrophy2Prof. Johan Auwerx, EPFL, Lausanne
2019Tamoxifen in Duchenne muscular dystrophy (TAMDMD) 2Dr. med. Dirk Fischer, UKBB Basel
2019DNA aptamers against the DUX4 protein reveal novel therapeutic implications for FSHD2Dr. Jochen Kinter and Dr. Christian Klingler, University of Basel
2019Facilitating diagnosis of critical illness myopathy using muscle excitability testing 2Prof. med. Werner J. Z'Graggen, Inselspital Bern
2019Rapid Exploratory Imaging for High-resolution and Whole Extremity Coverage in MR Neurography2Dr. Olivier Scheidegger, Inselspital Bern
2019Deciphering novel mechanisms and effectors contributing to muscle dysfunction in Myotonic Dystrophy Type I 1Prof. Perrine Castets, University of Geneva
2018Can HDAC/DNA methyltransferase inhibitors improve muscle function in a congenital myopathy caused by recessive RYR1 mutations?2Prof. Francesco Zorzato and Prof. Susan Treves, University Hospital Basel
2018Identification of the critical regulators of protein synthesis and degradation in human muscle atrophy2Dr. Lionel Tintignac and Dr. Nitish Mittal, University of Basel
2018Exploring peripheral B-cell-helper T cell phenotypes in the blood of patients with Myasthenia gravis using mass cytometry (CyTOF)1Dr. med. Bettina Schreiner, University Hospital Zürich
2018Molecular signature, metabolic profile and therapeutic potential of human myogenic reserve cells3Dr. Thomas Laumonier, University of Geneva
2018A multicenter cross-sectional and longitudinal study of the Swiss cohort of Merosin-negative congenital muscular dystrophy3Dr. med. Andrea Klein, UKBB Basel
2018Targeting NADPH oxidase 4 in models of Duchenne muscular dystrophy (extension of project 2016)1Dr. Hesham Hamed, University of Geneva
2017Characterizing the role of ER stress in C9orf72-linked ALS pathology2Prof. Smita Saxena, Inselspital, University of Bern
2017 Inducing mitophagy with Urolithin A to restore mitochondrial and muscle function in muscular dystrophy2Prof. Johan Auwerx, EPFL Lausanne
2017Exercise‐based interventions in dysferlinopathies2Prof. Christoph Handschin, Biozentrum Basel
2017Motor unit action potentials analysis in patients with myopathies with a new wireless portable and multichannel Surface EMG device (WPM-SEMG)2Prof. Alain Kälin, Neurocentro della Svizzera Italiana, Lugano
2017Role and therapeutic potential of PLIN3 in neuromuscular diseases2Dr. Francesca Amati, University of Lausanne
2017Changes in ventilation distribution in children with neuromuscular disease using the insufflator/exsufflator technique: An observational study 1Dr. med. Thomas Riedel, Kantonsspital Graubünden, Chur
2016Mechanism and function of genome organization in muscle development and integrity2Prof. Susan Gasser, Friederich Miescher Institute, Basel
2016Role and therapeutic potential of NADPH oxidases in a mouse model of Duchenne Muscular Dystrophy2Dr. Hesham Hamed, University of Geneva
2016Characterization of pathological pathways activated in muscles of patients with congenital myopathies with disturbed Ca2+ homeostasis2Prof. Susan Treves, Basel University Hospital
2016Creation of  a study team to conduct an SMA-1 clinical trial at the Centre for Neuromuscular Diseases at the University Children's Hospital Basel (UKBB)1Dr. med. Andrea Klein, Universitäts-Kinderspital beider Basel (UKBB)
2015Novel treatment to stop progressive neuropathy and muscle weakness in multifocal motor neuropathy3
Dr. Ruben Herrendorff, University of Basel
2015Understanding the pathomechanisms leading to muscle alterations in Myotonic Dystrophy type I3Dr. Perrine Castets, University of Basel
2015Automated volumetry and quantitative MRI to diagnose peripheral nerve lesions – translational proposal for a new clinical diagnostic imaging tool2
Dr. Olivier Scheidegger, Inselspital Bern
2015Novel approaches against Spinal Muscular Atrophy by targeting splicing regulators2Prof. Frédéric Allain, ETH Zürich
2015Protective effects and mechanisms of action of tamoxifen in mice with severe muscular diseases3Dr. Olivier Dorchies, University of Geneva
2015Role of the receptor FgfrL1 in the development of slow muscle fibers2Prof. Beat Trueb, University of Bern
2015Muscle velocity recovery cycles: A new tool for early diagnosis of critical illness myopathy1Prof. med. Werner J. Z'Graggen, Inselpital Bern
2014Generation of uncomitted human IPSC derived muscle stem cells for therapeutic applications3Dr. Florian Bentzinger,
Nestlé Institute of Health Sciences, Lausanne
2014Transposable vectors for dystrophin-expression in a murine model for muscular dystrophy3Prof. Nicolas Mermod,
University of Lausanne
2014Cardiac involvement in patients with Duchenne/Becker Muscular Dystrophy; an observational study1Dr. med. Andrea Klein, Children University Hospital Zürich
2014Deciphering the pathogenic mechanisms of C9ORF72 ALS
co-funded by ASLASI (Associazione Sclerosi Laterale Amiotrofica Svizzera Italiana)
3Dr. Magdalini Polymenidou,
University of Zürich
2014Development of magnetic resonance methods for functional imaging of the skeletal muscle2Dr. Francesco Santini,
Basel University Hospital
2013Enhancing estrogenic signalling to fight muscular dystrophies: Mechanisms of action and repurposing clinically approved drugs2Dr. Olivier Dorchies, University of Geneva
2013Mechanisms and therapeutic potential of modulating PGC‐1α to alter neuromuscular junction morphology and function2Prof. Christoph Handschin, University of Basel
2013Triggering human myoblast differentiation: from EGFR to myogenic transcription factors3Prof. Laurent Bernheim, University of Geneva
2013Improving cellular therapies of muscle dystrophies by uncovering epigenetic and signaling pathways of muscle formation
co-funded by Schweizerische Muskelgesellschaft
3Prof. Peter Meister, University of Bern
2013Protein engineering in an attempt to increase the mechanical, integrin dependent cytoskeleton-matrix linkage in muscle fibers1Prof. Bernhard Wehrle-Haller, University of Geneva
2012Evaluation of novel treatment strategies for dysferlinopathies in mouse models1Prof. med. Michael Sinnreich, University Hospital Basel
2012Cell therapy of LGMD2D by donor HLA-characterized human mesoangioblasts (hMABs) produced in GMP conditions3Dr. Marisa Jaconi, University of Geneva
2012In search of small molecules targeting protein-RNA complex: a novel approach against Spinal Muscular Atrophy3Prof. Frédéric Allain, ETH Zürich
2012Targeting ER stress response: a potential mechanism for neuroprotection in Amyotrophic Lateral Sclerosis
co-funded by ASLASI (Associazione Sclerosi Laterale Amiotrofica Svizzera Italiana)
1Prof. Smita Saxena, University of Bern
2012Restoration of autophagy as a new strategy for the treatment of congenital muscular dystrophies3Prof. Markus A. Rüegg, University of Basel
2011SRP-35, a newly identified skeletal muscle protein linking excitation-contraction coupling to activation of metabolism1Prof. Susan Treves, University of Basel

Muscle veocity recovery cycles: a new tool for characterization of muscle disease in vivo
co-funded by Schweizerische Muskelgesellschaft

1.5Prof. med. Werner J. Z'Graggen, Inselspital Bern
2011Excessive neurotrypsin activation and agrin cleavage-a pathogenic condition leading to sarcopenia-like muscle atrophy?1Prof. Peter Sonderegger, University of Zürich


Von 1987 bis 2010 hat die Stiftung 107 weitere Forschungsprojekte finanziert.